missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ TNFR2 (soluble) Monoclonal Antibody (897C2G9)
Mouse Monoclonal Antibody
Brand: Invitrogen™ AHR3022
This item is not returnable.
View return policy
Description
This product is recommended as a capture antibody in Sandwich ELISA applications. This clone can also be referred to as clone number 897C 2G9 1H3.
TNFR2 (tumor necrosis factor receptor superfamily member 1B) is a receptor with high affinity for TNFSF2/TNF-alpha. It has a much lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. TNFR2 mediates most of the metabolic effects of TNF-alpha.
Specifications
TNFR2 (soluble) | |
Monoclonal | |
1 mg/mL | |
PBS with 0.5mg/mL sodium azide; pH 7.4 | |
P20333 | |
Tnfrsf1b | |
Purified recombinant human soluble TNF Receptor II. | |
500 μg | |
Primary | |
Human | |
Antibody | |
IgG1 |
ELISA | |
897C2G9 | |
Unconjugated | |
Tnfrsf1b | |
CD120b; Etanercept; p75; p75 TNF receptor; p75 TNFR; p75TNFR; p80 TNF-alpha receptor; sCD120b; soluble CD120b; soluble TNFR1B variant 1; soluble TNFR2; sTNF R2; sTNFR 2; sTNFR2; TBP-2; TBPII; TNF receptor beta chain; TNF receptor superfamily member 1B; TNF-alphaR2; TNFalpha-R2; TNFBR; TNFR; TNFR II; Tnfr-1; TNFR1B; TNFR2; TNF-R2; Tnfr-2; TNF-R75; TNFR80; TNFRII; TNF-RII; TNF-R-II; TNFR-II; TNFRSF1B; tumor necrosis factor beta receptor; tumor necrosis factor binding protein 2; Tumor necrosis factor receptor; tumor necrosis factor receptor 2; Tumor necrosis factor receptor superfamily member 1B; Tumor necrosis factor receptor superfamily member 1b, membrane form; tumor necrosis factor receptor superfamily, member 1B; tumor necrosis factor receptor type II; Tumor necrosis factor-binding protein 2 | |
Mouse | |
Protein A | |
RUO | |
7133 | |
4°C | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction